A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
← catalyst calendarNCT06120075 · readout ≤ 102 d
Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
91estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-19 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Cancer
Interventions
- Drug: AB801
- Drug: Docetaxel
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events
measured Up to 2 years
Dose Escalation Cohorts: Number of Participants With Dose-Limiting Toxicities (DLTs)
measured Up to 2 years
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed